Phase 2 N=42 Statins and Cerebral Blood Flow in Subarachnoid Hemorrhage (SAH)
Subarachnoid Hemorrhage
Primary: Resting Cerebral Blood Flow During Peak Period of Vasospasm Risk — .34; .30 mL/100 g/min
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=20 Acute Airway Vascular Smooth Muscle Effects of Inhaled Budesonide
Asthma
Primary: Airway Blood Flow (Qaw) — 22.3; 29.4; 34.1; 28.2 percentage of change from baseline
N/A N=121 Nicotine Effects on Endophenotypes of Schizophrenia
Schizophrenia
Primary: Error Percentage in Antisaccade Task — 22.6; 29.1 Error Percentage in Antisaccade Task — p=<0.05
Phase 3 N=688 Phase 3 Papulopustular Rosacea Study
Papulopustular Rosacea
Primary: Success Rate — 40.1; 18.8 Percentage of participants — p=<0.001
Phase 2 N=125 NSAID Phase II for Non-central Involved Diabetic Macular Edema (DME)
Diabetic Macular Edema
Primary: Mean Change in Optical Coherence Tomography Measure Retinal Volume, mm3 — 0.02; -0.03 mm3
Phase 3 N=807 A Study in Participants With Type 2 Diabetes Mellitus (AWARD-3)
Diabetes Mellitus, Type 2
Primary: Change From Baseline to 26-week Endpoint in Glycosylated Hemoglobin (HbA1c) — -0.78; -0.71; -0.56 percentage of glycosylated hemoglobin — p=<0.001
N/A N=605 Non-Interventional Observational Study With Viramune Plus Antiretroviral in HIV Infected Patients
HIV Infections
Primary: Number of Participants With Treatment Emergent Adverse Events (AE) and All Serious AEs — 168; 110; 51; 10 participants
Phase 3 N=120 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Trivalent Split Virion Influenza Vaccine Fluviral™ (2013-2014 Season) in Adults Aged 18 Years and Older
Influenza
Primary: Humoral Immune Response in Terms of Haemagglutination Inhibition (HI) Antibody Titers Against Each of the Three Vaccine Influenza Strains — 61.0; 65.7; 337.4; 207.5 Titer
N/A N=80 Modifying Cervical Bishop Scoring System
Failed Induction of Labor
Primary: Area Under Receiver Operating Characteristic Curve (ROC) for Modified Bishop Score — 0.916 probability — p=0.000
Phase 3 N=92 Methylphenidate Transdermal System (MTS) in the Treatment of Adult ADHD
Attention Deficit Hyperactivity Disorder
Primary: Wender Reimherr Adult Attention Deficit Disorder Scale — 11.0; 17.9 units on a scale — p=.001
Phase 3 N=354 Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease
Advanced Parkinson's Disease
Primary: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths and Discontinuations Due to AEs — 8; 7; 111; 108 participants
Phase 3 N=810 A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2)
Diabetes Mellitus, Type 2
Primary: Change From Baseline to 52 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c) — -1.08; -0.76; -0.63 percentage of glycosylated hemoglobin — p=<0.001
Phase 1 N=76 Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL
Non-Hodgkin's Lymphoma, Relapsed
Primary: Number of Participants With Adverse Events — 12; 13; 6; 9 participants
Phase 3 N=71 Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
Advanced Parkinson's Disease
Primary: Change From Baseline to Week 12 in Average Daily Normalized "Off" Time — -4.04; -2.14 hours — p=0.0015
N/A N=25 Rehabilitation of Idiopathic Pulmonary Fibrosis (IPF) Patients
Idiopathic Pulmonary Fibrosis
Primary: 6 Minute Walk Distance — -6.2; -15.3 meters